Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

We feel now is a pretty good time to analyse Vertex, Inc.'s ( NASDAQ:VERX ) business as it appears the company may ...

Vertex Minerals Ltd. is pleased to announce that its Ordinary Shares have been approved to trade on the OTCQB Venture Market in the United States of America and have commenced trading under the ticker ...

A Connecticut-based financial services company has been named the No. 2 best place to work in the United States, according to a new Fortune survey.Synchrony, a Stamford-based finance and insurance ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

The ASX took a hit on tariff fears with markets dropping globally. Gold soared to new highs and eyes turn to the RBA’s rate ...